Related references
Note: Only part of the references are listed.Auristatin Antibody Drug Conjugate Physical Instability and the Role of Drug Payload
Yilma T. Adem et al.
BIOCONJUGATE CHEMISTRY (2014)
Site-specific antibody drug conjugates for cancer therapy
Siler Panowski et al.
MABS (2014)
Antibody-drug conjugates Present and future
Alain Beck et al.
MABS (2014)
Antibody-Drug Conjugates for the Treatment of Cancer
John A. Flygare et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2013)
Acid-cleavable thiomaleamic acid linker for homogeneous antibody-drug conjugation
Lourdes Castaneda et al.
CHEMICAL COMMUNICATIONS (2013)
A mild synthesis of N-functionalised bromomaleimides, thiomaleimides and bromopyridazinediones
Lourdes Castaneda et al.
TETRAHEDRON LETTERS (2013)
Homogeneous antibody fragment conjugation by disulfide bridging introduces 'spinostics'
Felix F. Schumacher et al.
SCIENTIFIC REPORTS (2013)
Reagents for Astatination of Biomolecules. 6. An Intact Antibody Conjugated with a Maleimido-closo-Decaborate(2-) Reagent via Sulfhydryl Groups Had Considerably Higher Kidney Concentrations than the Same Antibody Conjugated with an Isothiocyanato-closo-Decaborate(2-) Reagent via Lysine Amines
D. Scott Wilbur et al.
BIOCONJUGATE CHEMISTRY (2012)
Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
Ben-Quan Shen et al.
NATURE BIOTECHNOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Synthesis of site-specific antibody-drug conjugates using unnatural amino acids
Jun Y. Axup et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody-Drug Conjugates in Rats
C. Andrew Boswell et al.
BIOCONJUGATE CHEMISTRY (2011)
In Situ Maleimide Bridging of Disulfides and a New Approach to Protein PEGylation
Felix F. Schumacher et al.
BIOCONJUGATE CHEMISTRY (2011)
Tunable reagents for multi-functional bioconjugation: reversible or permanent chemical modification of proteins and peptides by control of maleimide hydrolysis
Chris P. Ryan et al.
CHEMICAL COMMUNICATIONS (2011)
The development of pyrrolobenzodiazepines as antitumour agents
John A. Hartley
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
Synthesis and Evaluation of Hydrophilic Linkers for Antibody-Maytansinoid Conjugates
Robert Y. Zhao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Analytical methods for physicochemical characterization of antibody drug conjugates
Aditya Wakankar et al.
MABS (2011)
Physicochemical Stability of the Antibody-Drug Conjugate Trastuzumab-DM1: Changes due to Modification and Conjugation Processes
Aditya A. Wakankar et al.
BIOCONJUGATE CHEMISTRY (2010)
Engineered Thio-Trastuzumab-DM1 Conjugate with an Improved Therapeutic Index to Target Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
Jagath R. Junutula et al.
CLINICAL CANCER RESEARCH (2010)
Antibody-drug conjugates: targeted drug delivery for cancer
Stephen C. Alley et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Chemoenzymatic methods for site-specific protein modification
David Rabuka
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Novel Peptide Linkers for Highly Potent Antibody-Auristatin Conjugate
Svetlana O. Doronina et al.
BIOCONJUGATE CHEMISTRY (2008)
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
Jagath R. Junutula et al.
NATURE BIOTECHNOLOGY (2008)
Paul Ehrlich's magic bullet concept: 100 years of progress
Klaus Strebhardt et al.
NATURE REVIEWS CANCER (2008)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment
Charlotte F. McDonagh et al.
PROTEIN ENGINEERING DESIGN & SELECTION (2006)
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity
SO Doronina et al.
BIOCONJUGATE CHEMISTRY (2006)
A comparative study of bioorthogonal reactions with azides
Nicholas J. Agard et al.
ACS CHEMICAL BIOLOGY (2006)
Synthesis of substituted bis(heteroaryl)maleimides
M Dubernet et al.
TETRAHEDRON (2005)
EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer
WG Mao et al.
CANCER RESEARCH (2004)
Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
KJ Hamblett et al.
CLINICAL CANCER RESEARCH (2004)
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina et al.
NATURE BIOTECHNOLOGY (2003)
Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: Model studies of enzymatic drug release and antigen-specific in vitro anticancer activity
GM Dubowchik et al.
BIOCONJUGATE CHEMISTRY (2002)
Share Paper
